A new approach to estimate vaccine efficacy based on immunogenicity data applied to influenza vaccines administered by the intradermal or intramuscular routes

Human Vaccines

Volumn 6, Issue 10, 2010, Pages 841-848

  Coudeville, Laurent ^a   Andre, Philippe ^a   Bailleux, Fabrice ^a   Weber, Françoise ^a   Plotkin, Stanley ^b  

^a SANOFI PASTEUR   (France)

^b Vaxconsult   (United States)

Author keywords

Efficacy; Hemagglutination inhibition titers; Influenza; Intradermal; Intramuscular; Model; Vaccine

Indexed keywords

IDFLU; INFLUENZA VACCINE; INTANZA; TRIPLE VACCINE; UNCLASSIFIED DRUG;

AGED; ANTIBODY TITER; ARTICLE; CLINICAL TRIAL; DRUG EFFICACY; HEMAGGLUTINATION INHIBITION TEST; HUMAN; IMMUNOGENICITY; INFLUENZA A (H1N1); INFLUENZA A (H3N2); INFLUENZA B; INFLUENZA VACCINATION; MAJOR CLINICAL STUDY;

AGED; AGED, 80 AND OVER; ANTIBODIES, VIRAL; CLINICAL LABORATORY TECHNIQUES; DOSE-RESPONSE RELATIONSHIP, IMMUNOLOGIC; FEMALE; HEMAGGLUTINATION INHIBITION TESTS; HUMANS; INFLUENZA VACCINES; INFLUENZA, HUMAN; INJECTIONS, INTRADERMAL; INJECTIONS, INTRAMUSCULAR; MALE; MIDDLE AGED; RANDOMIZED CONTROLLED TRIALS AS TOPIC; VACCINES, INACTIVATED;

EID: 78649371234     PISSN: 15548600     EISSN: 15548619     Source Type: Journal    
DOI: 10.4161/hv.6.10.12636     Document Type: Article

References (36)

1. WHO. Influenza. Factsheet number 211, In: World Health Organization, ed. 2008.
2. Committee for Medicinal Products for Human Use (CHMP). Guideline on Clinical Evaluation of New Vaccines 2005.
3. DHHS/FDA/CBER. Guidance for Industry, Clinical Data Needed to Support the Licensure of Pandemic Influenza Vaccines, Draft Guidance 2006.
4. de Jong JC, Palache AM, Beyer WE, Rimmelzwaan GF, Boon AC, Osterhaus AD. Haemagglutination-inhibiting antibody to influenza virus. Dev Biol (Basel) 2003; 115:63-73.
5. Hobson D, Curry RL, Beare AS, Ward-Gardner A. The role of serum haemagglutination-inhibiting antibody in protection against challenge infection with influenza A2 and B viruses. J Hyg (Lond) 1972; 70:767-77.
6. Masurel N, Laufer J. A one-year study of trivalent influenza vaccines in primed and unprimed volunteers: immunogenicity, clinical reactions and protection. J Hyg (Lond) 1984; 92:263-76.
7. Palache AM. Influenza vaccines. A reappraisal of their use. Drugs 1997; 54:841-56.
8. Plotkin SA. Vaccines: correlates of vaccine-induced immunity. Clin Infect Dis 2008; 47:401-9.
9. Wesselius-de Casparis A, Masurel N, Kerrebijn KF. Field trial with human and equine influenza vaccines in children: protection and antibody titres. Bull World Health Organ 1972; 46:151-7.
10. Nauta JJ, Beyer WE, Osterhaus AD. On the relationship between mean antibody level, seroprotection and clinical protection from influenza. Biologicals 2009; 37:216-21.
11. Coudeville L, Bailleux F, Riche B, Megas F, Andre P, Ecochard R. Relationship between haemagglutination-inhibiting antibody titres and clinical protection against influenza: development and application of a bayesian random-effects model. BMC. Med Res Methodol 2010; 10:18.
12. Arnou R, Icardi G, De Decker M, Ambrozaitis A, Kazek MP, Weber F, et al. Intradermal influenza vaccine for older adults: a randomized controlled multicenter phase III study. Vaccine 2009; 27:7304-12.
13. Holland D, Booy R, De Looze F, Eizenberg P, McDonald J, Karrasch J, et al. Intradermal influenza vaccine administered using a new microinjection system produces superior immunogenicity in elderly adults: a randomized controlled trial. J Infect Dis 2008; 198:650-8.
14. Jefferson TO, Rivetti D, Di Pietrantoni C, Rivetti A, Demicheli V. Vaccines for preventing influenza in healthy adults. Cochrane Database Syst Rev 2007; 2.
15. Rivetti D, Jefferson T, Thomas R, Rudin M, Rivetti A, Di Pietrantonj C, et al. Vaccines for preventing influenza in the elderly. Cochrane Database Syst Rev 2006; 3: CD004876.
16. Wood JM, Gaines-Das RE, Taylor J, Chakraverty P. Comparison of influenza serological techniques by international collaborative study. Vaccine 1994; 12:167-74. (Pubitemid 24041936)
17. Beyer WE, Palache AM, Luchters G, Nauta J, Osterhaus AD. Seroprotection rate, mean fold increase, seroconversion rate: which parameter adequately expresses seroresponse to influenza vaccination? Virus Res 2004; 103:125-32.
18. McMurry JA, Johansson BE, De Groot AS. A call to cellular & humoral arms: enlisting cognate T cell help to develop broad-spectrum vaccines against influenza A. Hum Vaccin 2008; 4:148-57.
19. McElhaney JE, Xie D, Hager WD, Barry MB, Wang Y, Kleppinger A, et al. T cell responses are better correlates of vaccine protection in the elderly. J Immunol 2006; 176:6333-9.
20. Prentice RL. Surrogate endpoints in clinical trials: definition and operational criteria. Stat Med 1989; 8:431-40.
21. Qin L, Gilbert PB, Corey L, McElrath MJ, Self SG. A framework for assessing immunological correlates of protection in vaccine trials. J Infect Dis 2007; 196:1304-12.
22. Dunning AJ. A model for immunological correlates of protection. Stat Med 2006; 25:1485-97.
23. Bell JA, Ward TG, Kapikian AZ, Shelokov A, Reichelderfer TE, Huebner RJ. Artificially induced Asian influenza in vaccinated and unvaccinated volunteers. J Am Med Assoc 1957; 165:1366-73.
24. Clark A, Potter CW, Jennings R, Nicholl JP, Langrick AF, Schild GC, et al. A comparison of live and inactivated influenza A (H1N1) virus vaccines. 1. Short-term immunity. J Hyg (Lond) 1983; 90:351-9.
25. Clark A, Potter CW, Jennings R, Nicholl JP, Langrick AF, Schild GC, et al. A comparison of live and inactivated influenza A (H1N1) virus vaccines. 2. Long-term immunity. J Hyg (Lond) 1983; 90:361-70.
26. Goodeve A, Potter CW, Clark A, Jennings R, Schild GC, Yetts R. A graded-dose study of inactivated, surface antigen influenza B vaccine in volunteers: reactogenicity, antibody response and protection to challenge virus infection. J Hyg (Lond) 1983; 90:107-15.
27. Potter CW, Jennings R, Nicholson K, Tyrrell DA, Dickinson KG. Immunity to attenuated influenza virus WRL 105 infection induced by heterologous, inactivated influenza A virus vaccines. J Hyg (Lond) 1977; 79:321-32.
28. Dowdle WR, Coleman MT, Mostow SR, Kaye HS, Schoenbaum SC. Inactivated influenza vaccines. 2. Laboratory indices of protection. Postgrad Med J 1973; 49:159-63.
29. Eaton MD, Meiklejohn G. Vaccination against Influenza. A study in California during the epidemic of 1943-44. Am J Hyg 1945; 42:28-44.
30. Hirota Y, Kaji M, Ide S, Kajiwara J, Kataoka K, Goto S, et al. Antibody efficacy as a keen index to evaluate influenza vaccine effectiveness. Vaccine 1997; 15:962-7. (Pubitemid 27308571)
31. Meiklejohn G, Weiss DL, Shragg RI, Lennette EH. Evaluation of monovalent influenza virus vaccines. I. Observations on antibody response following vaccination. Am J Hyg 1952; 55:1-11.
32. Salk JE, Menke WJ, Francis T. A clinical, epidemiological and immunological evaluation of vaccination against epidemic influenza. Am J Hyg 1945; 42:57-93.
33. Evans AS. Serologic studies of acute respiratory infections in military personnel. Yale J Biol Med 1975; 48:201-9.
34. Farnik J, Bruj J. An outbreak of influenza A2 in a population with a known antibody profile. J Infect Dis 1966; 116:425-8.
35. Fox JP, Cooney MK, Hall CE, Foy HM. Influenzavirus infections in Seattle families, 1975-1979. II. Pattern of infection in invaded households and relation of age and prior antibody to occurrence of infection and related illness. Am J Epidemiol 1982; 116:228-42.
36. Greenberg SB, Couch RB, Kasel JA. An outbreak of an influenza type A variant in a closed population: The effect of homologous and heterologous antibody on infection and illness. Am J Epidemiol 1974; 100:209-15.